Physician profile

Sheigh N Sander

Obstetrics & Gynecology · Saint Louis, MO

NPI 1215347281

$771.28

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$8.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Covidien LP $540.00 2019
Abbvie INC. $61.39 2021
Evofem Biosciences, INC. $36.23 2021
Avion Pharmaceuticals $26.55 2021
Organon LLC $23.92 2021-2024
Pharmacosmos Therapeutics INC. $19.66 2021
Bayer Healthcare Pharmaceuticals INC. $18.24 2021
Agile Therapeutics, INC. $17.37 2021
Becton, Dickinson and Company $14.70 2021
Coopersurgical, INC. $13.22 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sheigh N Sander

$771.28

in general payments reported 2019-2025

Years
2019-2024
Top company
Covidien LP

https://glasscript.com/doctor/682824/sheigh-n-sander

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.